In December 2019, Don was examined by five neurologists and two neuropsychologists who had observed him over the past year.  All said they couldn't believe he was the same man they had seen before.  The changes had been remarkable.  Two days later, we were notified that his trial was terminated.

​

It took us time to realize Biogen had halted another trial utilizing BIIB092, Gosuranemab because it didn't meet its endpoint goals. However, the data from the TauBasket trial has NOT been evaluated.